Skip to main content
. Author manuscript; available in PMC: 2013 Jun 3.
Published in final edited form as: Gynecol Oncol. 2011 Jun 17;122(3):521–526. doi: 10.1016/j.ygyno.2011.04.041

Table 3.

Progression free and overall survival by patient characteristics.

Characteristic No. of patients PFS OS


Median (months) P Median (months) P
Age group, years
 < 50 139 39.3 0.0843 N/A 0.0004
 50–59 102 29.5 70.3
 60–69 102 34.2 N/A
 70+ 74 25.3 52.2
Race
 White 359 33.1 0.6665 71.2 0.1964
 Black 26 27.2 55.1
 Other 32 39.3 82.4
GOG performance status
 0 193 43.3 0.0037 N/A 0.0002
 1 200 29.0 64
 2 24 27.4 55.1
Histology
 Serous 265 32.9 0.0376 71.2 < .0001
 Endometrioid 43 37.2 N/A
 Clear cell 29 26.2 43.3
 Mucinous 16 12.9 19.6
 Mixed epithelial 35 56.7 79.8
 Other 29 40.4 65.1
Tumor grade
 1 60 54.4 0.1311 N/A 0.2444
 2 129 32.1 66.9
 3 228 31.9 70.3
Initial disease distribution
 MD 59 47.6 0.0139 N/A 0.0044
 APD 260 34.8 79.8
 UAD 98 23.9 56.1

Abbreviations: PFS, progression free survival; OS, overall survival; GOG, Gynecologic Oncology Group; MD, minimal disease; APD, abdominal peritoneal disease; UAD, upper abdominal disease.